Combination of Pembrolizumab with Electrochemotherapy in Cutaneous Metastases from Melanoma: A Comparative Retrospective Study from the InspECT and Slovenian Cancer Registry.
electrochemotherapy
metastatic melanoma
pembrolizumab
skin metastases
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
25 Aug 2021
25 Aug 2021
Historique:
received:
06
07
2021
revised:
14
08
2021
accepted:
19
08
2021
entrez:
10
9
2021
pubmed:
11
9
2021
medline:
11
9
2021
Statut:
epublish
Résumé
Electrochemotherapy (ECT) is an effective locoregional therapy for cutaneous melanoma metastases and has been safely combined with immune checkpoint inhibitors in preliminary experiences. Since ECT is known to induce immunogenic cell death, its combination with immune checkpoint inhibitors might be beneficial. In this study, we aimed to investigate the effectiveness of ECT on cutaneous melanoma metastases in combination with pembrolizumab. We undertook a retrospective matched cohort analysis of stage IIIC-IV melanoma patients, included in the International Network for sharing practices of ECT (InspECT) and the Slovenian Cancer Registry. We compared the outcome of patients who received the following treatments: (a) pembrolizumab alone, (b) pembrolizumab plus ECT, and (c) ECT. The groups were matched for age, sex, performance status, and size of skin metastases. The local objective response rate (ORR) was higher in the pembrolizumab-ECT group than in the pembrolizumab group (78% and 39%,
Identifiants
pubmed: 34503099
pii: cancers13174289
doi: 10.3390/cancers13174289
pmc: PMC8428335
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Javna Agencija za Raziskovalno Dejavnost RS
ID : P3-0003
Références
Acta Oncol. 2011 Jun;50(5):621-9
pubmed: 21574833
Melanoma Res. 2010 Jun;20(3):227-32
pubmed: 20449885
Melanoma Res. 2021 Aug 1;31(4):290-297
pubmed: 34039942
Cancer Immunol Immunother. 2015 Oct;64(10):1315-27
pubmed: 26067277
Q J Nucl Med Mol Imaging. 2020 Jun;64(2):152-161
pubmed: 32107902
Front Immunol. 2019 Feb 08;10:168
pubmed: 30800125
Cell. 2015 Sep 10;162(6):1186-90
pubmed: 26359975
ESMO Open. 2021 Jun;6(3):100136
pubmed: 33930656
Semin Oncol. 2019 Apr;46(2):173-191
pubmed: 31122761
J Clin Oncol. 2014 Oct 1;32(28):3144-55
pubmed: 25154827
Eur J Surg Oncol. 2021 Aug;47(8):1836-1846
pubmed: 33726951
Eur Respir Rev. 2019 Nov 6;28(154):
pubmed: 31694838
Cancer Metastasis Rev. 2016 Jun;35(2):165-77
pubmed: 26993326
Anticancer Drugs. 2018 Feb;29(2):190-196
pubmed: 29271783
Eur J Cancer. 2021 Jul;152:139-154
pubmed: 34102453
Cancer Immunol Immunother. 2016 Aug;65(8):951-9
pubmed: 27294607
Clin Exp Metastasis. 2016 Dec;33(8):787-798
pubmed: 27475809
Ann Surg Oncol. 2008 Aug;15(8):2215-22
pubmed: 18498012
Oncoimmunology. 2014 Apr 15;3:e28131
pubmed: 25083316
Clin Cosmet Investig Dermatol. 2017 Aug 24;10:325-339
pubmed: 28883738
Sci Rep. 2020 Feb 10;10(1):2291
pubmed: 32042142
J Control Release. 2021 Apr 10;332:623-635
pubmed: 33705828
Cancer Immunol Res. 2020 Feb;8(2):246-254
pubmed: 31852717
J Immunother Cancer. 2021 Feb;9(2):
pubmed: 33608376
Int J Dermatol. 2019 Aug;58(8):865-870
pubmed: 30479009
Melanoma Res. 2021 Jun 1;31(3):232-241
pubmed: 33741814
Acta Oncol. 2018 Jul;57(7):874-882
pubmed: 29577784
Cancer Manag Res. 2019 May 15;11:4297-4312
pubmed: 31190995
Ann Surg Oncol. 2020 Dec;27(13):5107-5118
pubmed: 32918177
Eur J Dermatol. 2015 May-Jun;25(3):271-2
pubmed: 26055291
Ann Oncol. 2020 Nov;31(11):1449-1461
pubmed: 32763452
J Plast Reconstr Aesthet Surg. 2020 Jul;73(7):1263-1267
pubmed: 32245735
Eur J Cancer. 2020 Oct;138:30-40
pubmed: 32836172
Br J Surg. 2012 Jun;99(6):821-30
pubmed: 22508342
Br J Radiol. 2018 Apr;91(1084):20170457
pubmed: 29172675
N Engl J Med. 2015 May 21;372(21):2006-17
pubmed: 25891304
Int J Cancer. 2020 Sep 15;147(6):1509-1518
pubmed: 31997345
Br J Dermatol. 2017 Jun;176(6):1475-1485
pubmed: 28118487
Nat Rev Cancer. 2020 Nov;20(11):662-680
pubmed: 32753728
Oncoimmunology. 2015 May 22;4(6):e1008842
pubmed: 26155423
Clin Cancer Res. 2020 Jun 15;26(12):2827-2837
pubmed: 32376655
Trends Cancer. 2020 Jul;6(7):605-618
pubmed: 32610070
J Natl Compr Canc Netw. 2016 May;14(5 Suppl):638-40
pubmed: 27226502
Ann Transl Med. 2019 Mar;7(Suppl 1):S24
pubmed: 31032304